Asciminib in chronic myeloid leukemia: many questions still remain to be answered

Blood Cancer J. 2021 Apr 29;11(4):81. doi: 10.1038/s41408-021-00475-7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-abl / antagonists & inhibitors
  • Pyrazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • asciminib
  • Niacinamide
  • ABL1 protein, human
  • Proto-Oncogene Proteins c-abl